No connection

Search Results

PRQR vs TNXP

PRQR
ProQR Therapeutics N.V.
BEARISH
Price
$1.99
Market Cap
$209.7M
Sector
Healthcare
AI Confidence
90%
TNXP
Tonix Pharmaceuticals Holding Corp.
BEARISH
Price
$14.34
Market Cap
$203.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
PRQR
--
TNXP
--
Forward P/E
PRQR
-4.23
TNXP
-2.78
P/B Ratio
PRQR
3.63
TNXP
0.75
P/S Ratio
PRQR
12.83
TNXP
15.54
EV/EBITDA
PRQR
-3.13
TNXP
0.11

Profitability

Gross Margin
PRQR
100.0%
TNXP
49.34%
Operating Margin
PRQR
-192.9%
TNXP
-895.84%
Profit Margin
PRQR
-258.05%
TNXP
0.0%
ROE
PRQR
-61.17%
TNXP
-64.48%
ROA
PRQR
-19.35%
TNXP
-35.71%

Growth

Revenue Growth
PRQR
6.1%
TNXP
108.8%
Earnings Growth
PRQR
--
TNXP
--

Financial Health

Debt/Equity
PRQR
0.32
TNXP
0.01
Current Ratio
PRQR
3.09
TNXP
7.42
Quick Ratio
PRQR
3.0
TNXP
6.96

Dividends

Dividend Yield
PRQR
--
TNXP
--
Payout Ratio
PRQR
0.0%
TNXP
0.0%

AI Verdict

PRQR BEARISH

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe fundamental weakness across all measured financial dimensions. While the company maintains a strong liquidity position with a Current Ratio of 3.09 and low Debt/Equity (0.32), it suffers from extreme operational inefficiency with a profit margin of -258.05%. There is a stark divergence between the objective financial data and the 'Strong Buy' analyst consensus, suggesting the valuation is based on speculative pipeline catalysts rather than current fiscal performance. The technical trend is entirely bearish (0/100), further compounding the negative outlook.

Strengths
Strong short-term liquidity (Current Ratio 3.09)
Low leverage (Debt/Equity 0.32)
Strong analyst conviction with a target price of $8.88
Risks
Critical fundamental failure (Piotroski F-Score 0/9)
Extreme negative profitability (Profit Margin -258.05%)
High valuation relative to sales (P/S 12.83)
TNXP BEARISH

TNXP exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -895.84%. While the company maintains a high current ratio (7.42) and low debt, these are likely the result of aggressive equity dilution rather than operational success, as evidenced by a -100% 5-year price return. Despite a 'strong_buy' analyst consensus and high revenue growth, the lack of earnings beats (0/4 in the last year) and a total collapse in long-term shareholder value indicate a high-risk profile. The disconnect between the analyst target price ($54.33) and the fundamental decay is extreme.

Strengths
Strong YoY revenue growth of 108.80%
High liquidity with a current ratio of 7.42
Very low debt-to-equity ratio (0.01)
Risks
Extreme operational inefficiency (Operating Margin -895.84%)
Critical financial health (Piotroski F-Score 1/9)
Consistent failure to meet earnings estimates (0/4 last 4 quarters)

Compare Another Pair

PRQR vs TNXP: Head-to-Head Comparison

This page compares ProQR Therapeutics N.V. (PRQR) and Tonix Pharmaceuticals Holding Corp. (TNXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile